SCHEMBL7950435

SCHEMBL7950435

CCCc1nn(C)c2c(=O)[nH]c(-c3cc(N)ccc3OCC)nc12

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.77
PDE5A O76074 17/20 0.75
PDE6C P51160 3/20 0.75
PDE1A P54750 2/20 0.75
PDE1B Q01064 2/20 0.75
PDE1C Q14123 2/20 0.75
MEN1 O00255 1/20 0.75
ALDH1A1 P00352 1/20 0.75
HPGD P15428 1/20 0.75
KDM4E B2RXH2 1/20 0.71
HDAC6 Q9UBN7 6/20 0.67
HDAC1 Q13547 4/20 0.67
HDAC2 Q92769 2/20 0.67
PDE3B Q13370 2/20 0.67
PDE3A Q14432 2/20 0.67
PDE2A O00408 1/20 0.67
ABCC4 O15439 1/20 0.67
ABCC5 O15440 1/20 0.67
PDE6D O43924 1/20 0.67
PDE8A O60658 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18715171 0.88 PDE5A (0.75) KMT2APDE5APDE6CPDE1APDE1B
SCHEMBL29416347 0.88 PDE5A (0.75) KMT2APDE5APDE6CPDE1APDE1B
SCHEMBL17390249 0.88 PDE5A (0.75) KMT2APDE5APDE6CPDE1APDE1B
SCHEMBL7950877 0.88 PDE5A (0.75) KMT2APDE5APDE6CPDE1APDE1B
SCHEMBL24893800 0.88 KMT2A (0.73) KMT2APDE5APDE6CPDE1APDE1B
SCHEMBL18714952 0.87 PDE5A (0.85) KMT2APDE5APDE6CPDE1APDE1B
SCHEMBL14836876 0.87 PDE5A (0.73) KMT2APDE5APDE6CPDE1APDE1B
SCHEMBL15996180 0.87 PDE5A (0.73) KMT2APDE5APDE6CPDE1APDE1B
SCHEMBL24051647 0.86 KMT2A (0.64) KMT2APDE5APDE6CPDE1APDE1B
SCHEMBL7950642 0.86 KMT2A (0.71) KMT2APDE5APDE6CPDE1APDE1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4259634-A1 NOVEL COMPOUNDS AS ANDROGEN RECEPTOR AND PHOSPHODIESTERASE DUAL INHIBITOR Ildong Pharmaceutical Co., Ltd. (KR) 2023-10-18 EP disclosed
US-11787812-B2 Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors ILDONG PHARMACEUTICAL CO., LTD. (KR) 2023-10-17 US disclosed
US-11787812-B2 Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors ILDONG PHARMACEUTICAL CO., LTD. (KR) 2023-10-17 US disclosed
CN-116848116-A Novel compounds as dual androgen receptor and phosphodiesterase inhibitors 日东制药株式会社 2023-10-03 CN disclosed
US-20220194948-A1 NOVEL COMPOUNDS AS ANDROGEN RECEPTOR AND PHOSPHODIESTERASE DUAL INHIBITOR ILDONG PHARACEUTICAL CO., LTD. (KR) 2022-06-23 US disclosed
WO-2022123310-A1 NOVEL COMPOUNDS AS ANDROGEN RECEPTOR AND PHOSPHODIESTERASE DUAL INHIBITOR ILDONG PHARMACEUTICAL CO., LTD. (KR) 2022-06-16 WO disclosed
EP-2961741-B1 NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES FUND PARA LA INVESTIG MEDICA APLICADA (ES) 2017-04-05 EP disclosed
US-9573956-B2 Compounds as dual inhibitors of phosphodiesterases and histone deacetylases FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) 2017-02-21 US disclosed
US-20160002246-A1 NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) 2016-01-07 US disclosed
EP-2961384-A1 A COMPOSITION COMPRISING A LIPID COMPOUND, A TRIGLYCERIDE, AND A SURFACTANT, AND METHODS OF USING THE SAME Pronova BioPharma Norge AS (NO) 2016-01-06 EP disclosed
EP-2961741-A1 NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES Fundacion para la Investigacion Medica Aplicada (ES) 2016-01-06 EP disclosed
WO-2014131855-A1 NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) 2014-09-04 WO disclosed
WO-2014132134-A1 A COMPOSITION COMPRISING A LIPID COMPOUND, A TRIGLYCERIDE, AND A SURFACTANT, AND METHODS OF USING THE SAME PRONOVA BIOPHARMA NORGE AS (NO) 2014-09-04 WO disclosed
US-6200980-B1 ADMINISTERING PHENYL PURINONE COMPOUND FOR TREATING PRECANCEROUS LEISONS CELL PATHWAYS, INC. 2001-03-13 US disclosed
EP-0526004-B1 Pyrazolopyrimidinone antianginal agents PFIZER LTD (GB) 1997-10-08 EP disclosed
US-5426107-A Treatment of cardiovascular disorders, asthma, allergies PFIZER INC. (US) 1995-06-20 US disclosed
US-5272147-A Pyrazolopyrimidinone antianginal agents PFIZER INC. (US) 1993-12-21 US disclosed
EP-0526004-A1 Pyrazolopyrimidinone antianginal agents Pfizer Limited (GB) 1993-02-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11787812-B2 Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors PDE5A, AR, PDE3A KMT2A 1830/4885PDE5A 1/4885PDE6C 38/4885
US-20160002246-A1 NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES PDE1A, HDAC1, HDAC2 KMT2A 98/4885PDE5A 24/4885PDE6C 236/4885
US-20220194948-A1 NOVEL COMPOUNDS AS ANDROGEN RECEPTOR AND PHOSPHODIESTERASE DUAL INHIBITOR AR, PDE5A, PDE1A KMT2A 2141/4885PDE5A 2/4885PDE6C 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.